193 related articles for article (PubMed ID: 26489961)
1. Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent.
Hasegawa M; Chino Y; Horiuchi N; Hachiuma K; Ishida M; Fukasawa Y; Nakai Y; Yamaguchi J
Xenobiotica; 2015; 45(12):1105-15. PubMed ID: 26489961
[TBL] [Abstract][Full Text] [Related]
2. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
[TBL] [Abstract][Full Text] [Related]
3. Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans.
Miyata A; Hasegawa M; Hachiuma K; Mori H; Horiuchi N; Mizuno-Yasuhira A; Chino Y; Jingu S; Sakai S; Samukawa Y; Nakai Y; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):332-345. PubMed ID: 27347703
[TBL] [Abstract][Full Text] [Related]
4. Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus.
Samukawa Y; Mutoh M; Chen S; Mizui N
Biol Pharm Bull; 2017; 40(8):1207-1218. PubMed ID: 28769002
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans.
Wang-Lakshman L; Mendonza AE; Huber R; Walles M; He Y; Jarugula V
Xenobiotica; 2021 Apr; 51(4):413-426. PubMed ID: 33413022
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects.
Miao Z; Nucci G; Amin N; Sharma R; Mascitti V; Tugnait M; Vaz AD; Callegari E; Kalgutkar AS
Drug Metab Dispos; 2013 Feb; 41(2):445-56. PubMed ID: 23169609
[TBL] [Abstract][Full Text] [Related]
7. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
8. Luseogliflozin for the treatment of type 2 diabetes.
Seino Y
Expert Opin Pharmacother; 2014 Dec; 15(18):2741-9. PubMed ID: 25359155
[TBL] [Abstract][Full Text] [Related]
9. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
[TBL] [Abstract][Full Text] [Related]
10. In vitro characterization of luseogliflozin, a potent and competitive sodium glucose co-transporter 2 inhibitor: Inhibition kinetics and binding studies.
Uchida S; Mitani A; Gunji E; Takahashi T; Yamamoto K
J Pharmacol Sci; 2015 May; 128(1):54-7. PubMed ID: 26003086
[TBL] [Abstract][Full Text] [Related]
11. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
12. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.
Zhang Y; Nakano D; Guan Y; Hitomi H; Uemura A; Masaki T; Kobara H; Sugaya T; Nishiyama A
Kidney Int; 2018 Sep; 94(3):524-535. PubMed ID: 30045814
[TBL] [Abstract][Full Text] [Related]
13. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.
Nakatsu Y; Kokubo H; Bumdelger B; Yoshizumi M; Yamamotoya T; Matsunaga Y; Ueda K; Inoue Y; Inoue MK; Fujishiro M; Kushiyama A; Ono H; Sakoda H; Asano T
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28777298
[TBL] [Abstract][Full Text] [Related]
14. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.
Mamidi RN; Cuyckens F; Chen J; Scheers E; Kalamaridis D; Lin R; Silva J; Sha S; Evans DC; Kelley MF; Devineni D; Johnson MD; Lim HK
Drug Metab Dispos; 2014 May; 42(5):903-16. PubMed ID: 24568888
[TBL] [Abstract][Full Text] [Related]
16. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
[TBL] [Abstract][Full Text] [Related]
17. Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study.
Samukawa Y; Sata M; Furihata K; Ito T; Ueda N; Ochiai H; Sakai S; Kumagai Y
Clin Pharmacol Drug Dev; 2017 Sep; 6(5):439-447. PubMed ID: 28783873
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
19. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.
Yabe D; Hamamoto Y; Seino Y; Kuwata H; Kurose T; Seino Y
Expert Opin Drug Saf; 2017 Oct; 16(10):1211-1218. PubMed ID: 28741382
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits, and dogs.
Mamidi RN; Mannens G; Annaert P; Hendrickx J; Goris I; Bockx M; Janssen CG; Kao M; Kelley MF; Meuldermans W
Drug Metab Dispos; 2007 Apr; 35(4):566-75. PubMed ID: 17220243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]